Levodopa in Parkinson's disease: effect on pulmonary function

1972 ◽  
Vol 130 (3) ◽  
pp. 346-348 ◽  
Author(s):  
K. K. Nakano
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Pulmonary Function ◽  
Disease Effect

Early morning akinesia in Parkinson's disease: Effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa

Neurology ◽  
1996 ◽  
Vol 46 (4) ◽  
pp. 1059-1062 ◽  
Author(s):  
R. Pahwa ◽  
K. Lyons ◽  
D. McGuire ◽  
R. Dubinsky ◽  
J. P. Hubble ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Sustained Release ◽  
Early Morning ◽  
Disease Effect

Risk Factors for Dementia in Parkinson's Disease: Effect of Education

1995 ◽  
Vol 15 (1) ◽  
pp. 20-25 ◽  
Author(s):  
S.L. Glatt ◽  
J.P. Hubble ◽  
K. Lyons ◽  
A. Paolo ◽  
A.I. Tröster ◽  
...  
Keyword(s):  
Risk Factors ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Disease Effect

scholarly journals Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l -DOPA treatment and changes in levodopa-induced dyskinesia

2017 ◽  
Vol 141 (4) ◽  
pp. 614-625 ◽  
Author(s):  
Andreas Dammann Andersen ◽  
Morten Blaabjerg ◽  
Michael Binzer ◽  
Akram Kamal ◽  
Helle Thagesen ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cerebrospinal Fluid ◽  
Cerebrospinal Fluid Levels ◽  
Disease Effect ◽  
Fluid Levels

Arm and leg swing during gait in Parkinson's disease: Effect of L-dopa and subthalamic nucleus stimulation

2008 ◽  
Vol 28 ◽  
pp. S19
Author(s):  
M. Ferrarin ◽  
P. Crenna ◽  
I. Carpinella ◽  
M. Rabuffetti ◽  
A.Marzegan ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Subthalamic Nucleus ◽  
Subthalamic Nucleus Stimulation ◽  
Disease Effect

Effects of Levodopa on Pulmonary Function in Parkinson's Disease

CHEST Journal ◽  
2001 ◽  
Vol 119 (2) ◽  
pp. 387-393 ◽  
Author(s):  
Bertrand Herer ◽  
Isabelle Arnulf ◽  
Bruno Housset
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Pulmonary Function

scholarly journals Detraining Effect on Pulmonary and Cardiovascular Autonomic Function and Functional Outcomes in Patients With Parkinson's Disease After Respiratory Muscle Training: An 18-Month Follow-Up Study

2021 ◽  
Vol 12 ◽  
Author(s):  
Chih-Cheng Huang ◽  
Yun-Ru Lai ◽  
Fu-An Wu ◽  
Nai-Ying Kuo ◽  
Ben-Chung Cheng ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Pulmonary Function ◽  
Functional Outcomes ◽  
Respiratory Muscle ◽  
Autonomic Function ◽  
Clinical Severity ◽  
Respiratory Muscle Training ◽  
Muscle Training ◽  
Cardiovascular Autonomic Function

Background: The effect of 3-month respiratory muscle training (RMT) on pulmonary and autonomic function and functional outcomes has been demonstrated in patients with Parkinson's disease (PD); however, there is a paucity of information on the durability of the training effect. In this study, we monitored the pulmonary and cardiovascular autonomic function and clinical severity scales until 18 months after the cessation of RMT to elucidate the detraining effect after RMT.Methods: All patients with PD receiving RMT were assessed with clinical severity scales as well as pulmonary and autonomic function tests at four different stages (baseline on enrollment, immediately after 3 months of RMT, and 6 and 18 months after cessation of RMT). A control group of PD patients who did not receive RMT was also recruited for comparison. Pulmonary function parameters, including forced vital capacity (FVC), forced expiratory volume in one second (FEV1), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP), were assessed. Cardiovascular autonomic function was assessed using measures including heart rate response to deep breathing (HRDB), Valsalva ratio, and baroreflex sensitivity. Clinical severity scores were also measured using the Hoehn and Yahr staging and the Unified Parkinson's Disease Rating Scale (UPDRS).Results: The results showed significant improvements in MIP, MEP, HRDB, and UPDRS immediately after RMT. Despite some decay, the improvements in pulmonary function (MIP and MEP) and functional outcomes (UPDRS) remained significant until 6 months of detraining (9 months after enrollment). However, the improvement in cardiovascular autonomic function (HRDB) was reversed after 6 months of detraining.Conclusions: Based on these findings, we recommend that RMT may be repeated after at least 6 months after previous session (9 months after enrollment) for patients with PD to maintain optimal therapeutic effects.

Sign in / Sign up

Export Citation Format

Share Document